Memory Peptide Care — Cognition Anchored | Kokorology
Coaching for people already on a cognition/memory peptide. Sleep, focus blocks, cognitive load coached around your clinician's protocol. €245/mo.
What's included
Every Kokorology Care package is one monthly plan: a monthly 1:1 with Sabin, weekly digital check-ins, and the Protocols app preloaded with the anchor-specific protocol. GLP-1 and taper packages add clinician intake and bi-monthly medical reviews. You keep your own doctor; we coach around them.
Who it's for
Adults already inside the protocol — on the peptide, mid-taper, mid-cycle, or working an anchor daily — who want structured coaching, not a course. Founders, operators, clinicians, athletes, and knowledge workers whose capacity to stay regulated is the whole job.
How it works
You book, complete the coaching onboarding, and land on a first 1:1 within seven days. Between sessions, weekly check-ins flag drift (sleep debt, HRV drop, protein floor missed, cortisol curve inverted) and route it to the next call. Cancel any time; keep your purchased Anchors.
What the evidence actually supports
Evidence reviewed: 2026-11-16
Semax
Preclinical neurotrophic effects and small regional studies are hypothesis-generating, not proof of reliable focus or memory gains in healthy adults. FDA's July 2026 briefing found insufficient human safety and effectiveness evidence; Semax is nonetheless one of the six peptides in the October 2026 US compounding policy.
No FDA-approved cognition indication or validated general-wellness intranasal schedule. Do not treat brain fog as a peptide deficiency: persistent or new cognitive symptoms need assessment, not a louder nootropic stack.
2026: easier US access is not new evidence
In April 2026 FDA took BPC-157, TB-500, Semax, Selank, MOTS-c, KPV, Epitalon, CJC-1295, AOD-9604, LL-37 and others off its Category 2 safety-risk list after their nominations were withdrawn. In July its compounding advisory committee narrowly recommended six of them for the 503A bulks list, over the objection of FDA's own drug reviewers, who found insufficient human safety and effectiveness evidence. On 30 October 2026 HHS published an interim policy: it will not act against US pharmacies compounding BPC-157, TB-500, MOTS-c, Epitalon, Semax or KPV if ten conditions are met.
That is an enforcement posture, not an FDA approval, a bulks-list rule or a clinical trial. It excludes 'research use only' vials and does not travel to Portugal, the UK or the EU, where a product presented or acting as a medicine still needs a marketing authorisation. Better sourcing lowers one risk, contamination, and leaves the efficacy question precisely where it was.